Sightera
Uses AI-guided drug discovery to study extreme patient biology first, aiming to uncover therapeutic insights from biotech research.
Overview
Sightera is a Belgian biotech developing an AI-enabled drug discovery approach that starts by learning from “extreme” patient biology. Its work is positioned around reversing conventional AI drug discovery, using patient-derived biological signals as the initial source for therapeutic insight. The company targets healthcare and biopharma applications where novel targets or mechanisms can be identified from unusual patient biology. Sightera raised a €3M pre-seed round in July 2026, providing early funding to advance its patient-first discovery model.
Funding History
Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from ‘extreme’ patient biology first
Frequently Asked Questions
- How much funding does AI Funding track for Sightera?
- AI Funding tracks €3M for Sightera across 1 funding round in this database.
- What does Sightera do?
- Sightera is a Belgian biotech developing an AI-enabled drug discovery approach that starts by learning from “extreme” patient biology. Its work is positioned around reversing conventional AI drug discovery, using patient-derived biological signals as the initial source for therapeutic insight. The company targets healthcare and biopharma applications where novel targets or mechanisms can be identified from unusual patient biology. Sightera raised a €3M pre-seed round in July 2026, providing early funding to advance its patient-first discovery model.
- Where is Sightera headquartered?
- Sightera is headquartered in Belgium.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.